BELLUS Health Inc. (BLU): Price and Financial Metrics
GET POWR RATINGS... FREE!
BLU POWR Grades
- Sentiment is the dimension where BLU ranks best; there it ranks ahead of 62.94% of US stocks.
- BLU's strongest trending metric is Growth; it's been moving up over the last 179 days.
- BLU ranks lowest in Momentum; there it ranks in the 12th percentile.
BLU Stock Summary
- BELLUS Health Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.79% of US listed stocks.
- For BLU, its debt to operating expenses ratio is greater than that reported by merely 5.91% of US equities we're observing.
- With a price/sales ratio of 40,978.19, BELLUS Health Inc has a higher such ratio than 99.98% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to BELLUS Health Inc are FSR, URG, CALT, MRSN, and EQS.
- Visit BLU's SEC page to see the company's official filings. To visit the company's web site, go to www.bellushealth.com.
BLU Stock Price Chart Interactive Chart >
BLU Price/Volume Stats
|Current price||$8.28||52-week high||$9.84|
|Prev. close||$7.63||52-week low||$2.60|
|Day high||$8.43||Avg. volume||941,982|
|50-day MA||$7.78||Dividend yield||N/A|
|200-day MA||$6.51||Market Cap||883.87M|
BELLUS Health Inc. (BLU) Company Bio
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Most Popular Stories View All
BLU Latest News Stream
|Loading, please wait...|
BLU Latest Social Stream
View Full BLU Social Stream
Latest BLU News From Around the Web
Below are the latest news stories about BELLUS Health Inc that investors may wish to consider to help them evaluate BLU as an investment opportunity.
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on BELLUS Health (BLU – Research Report) on January 24 and set a price target of $17.00. The company's shares closed last Wednesday at $5.90. According to TipRanks.com, Slutsky is ranked 0 out of 5 stars with an average return of -4.8% and a 34.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ventyx Biosciences, and Sierra Oncology. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $16.33 average price target, representing a 169.5% upside. In a report issued on January 25, H.C.
The week started in the best possible way for BELLUS Health (BLU) stock. While the main indexes bled in Monday’s session, BLU shares took the up escalator, surging by 48% following the announcement of positive clinical trial results. The company is testing lead candidate BLU-5937 as a potential therapy for refractory chronic cough (RCC). Topline results from the Phase 2b SOOTHE study of the P2X3 inhibitor showed the drug made a statistically meaningful difference; after 28 days of treatment there was a significant improvement to RCC patients' daily cough frequency, with a placebo-adjusted cough reduction of 34.4% in the 50mg cohort and a 34.2% drop in the 200mg group.
In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on BELLUS Health (BLU – Research Report), with a price target of $18.00. The company's shares closed last Monday at $8.30. According to TipRanks.com, Slutsky is a 3-star analyst with an average return of 6.1% and a 38.6% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ventyx Biosciences, and Sierra Oncology. Currently, the analyst consensus on BELLUS Health is a Strong Buy with an average price target of $16.00, implying a 92.8% upside from current levels.
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on BELLUS Health (BLU – Research Report) today and set a price target of $14.00. The company's shares closed last Monday at $8.63. According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.7% and a 40.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Deciphera Pharmaceuticals, and Global Blood Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $15.75 average price target, implying a 99.1% upside from current levels.
Arena Pharmaceuticals (ARNA) stock is flying higher on Monday thanks to a huge $6.7 billion acquisition deal with Pfizer (PFE).
BLU Price Returns